Company intends to pursue 505(b)(2) regulatory pathway for novel topical formulation of ketamine ENGLEWOOD CLIFFS, NJ, Oct. 03, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it is working with Premier Consulting as its regulatory…


Previous articleReunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference
Next articleatai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day